Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

for
Locally Advanced Pancreatic Adenocarcinoma
Location: Montreal, Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT06453486

Phase 2, Recruiting

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

for
Congenital Hyperinsulinism, Insulinoma
Location: Fort Worth TX
Sponsor: Cook Children's Health Care System

Sex: All

Age: 0 - 18

Code: NCT02021604

Phase 1, Recruiting

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma
Location: Detroit MI, Houston TX
Sponsor: Oncotelic Inc.

Sex: All

Age: 18+

Code: NCT06079346

Phase 2, Phase 3, Recruiting

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma
Location: Houston TX
Sponsor: Baylor College of Medicine

Sex: All

Age: 18+

Code: NCT05132504

Phase 2, Recruiting

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

for
Sarcoma,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT06503146

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

for
Pancreatic Ductal Adenocarcinoma (PDAC)
Location: Birmingham AL
Sponsor: ProDa BioTech, LLC

Sex: All

Age: 18+

Code: NCT06182072

Phase 1, Recruiting

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

for
Metastatic Pancreatic Neuroendocrine Tumor
Location: Chicago IL
Sponsor: University of Chicago

Sex: All

Age: 18+

Code: NCT06663072

Phase 1, Recruiting

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

for
Cancer Risk, Cancer Predisposition Syndrome,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 0+

Code: NCT05463796

Recruiting

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

for
Pancreatic Ductal Adenocarcinoma,
Location: Vancouver
Sponsor: British Columbia Cancer Agency

Sex: All

Age: 18+

Code: NCT06574620

Recruiting

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

for
Adenocarcinoma of the Pancreas
Location: Morgantown WV
Sponsor: West Virginia University

Sex: All

Age: 18+

Code: NCT04911816

Phase 1, Phase 2, Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

for
Gastric Cancer, Gastroesophageal Junction Cancer,
Location: Providence RI, Sherbrooke, Commack NY, Montreal,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06219941

Phase 2, Recruiting

AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

for
Pancreatic Ductal Adenocarcinoma
Location: West Islip NY, Buffalo NY
Sponsor: Roswell Park Cancer Institute

Sex: All

Age: 18+

Code: NCT06320717

Recruiting

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

for
Pancreatic Ductal Adenocarcinoma (mPDAC)
Location: La Jolla CA
Sponsor: University of California, San Diego

Sex: All

Age: 18+

Code: NCT06790602

Phase 2, Recruiting

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

for
Digestive System Neuroendocrine Tumor G1,
Location: Nashville TN
Sponsor: Vanderbilt-Ingram Cancer Center

Sex: All

Age: 18+

Code: NCT06016855

Recruiting

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

for
Pancreatic Adenocarcinoma
Location: Palo Alto CA
Sponsor: George Poultsides

Sex: All

Age: 19+

Code: NCT03384238

Phase 1, Phase 2, Recruiting

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma (PDAC)
Location: La Jolla CA
Sponsor: University of California, San Diego

Sex: All

Age: 18+

Code: NCT06639724

Phase 1, Recruiting

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma,
Location: San Francisco CA
Sponsor: University of California, San Francisco

Sex: All

Age: 18+

Code: NCT06600906

Recruiting

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

for
Pancreatic Ductal Adenocarcinoma
Location: Houston TX
Sponsor: The University of Texas Health Science Center, Houston

Sex: All

Age: 18+

Code: NCT06831136

Phase 2, Recruiting

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

for
Pancreatic Ductal Adenocarcinoma
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT05851924

Phase 2, Recruiting

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma
Location: Livingston NJ, New Brunswick NJ
Sponsor: Rutgers, The State University of New Jersey

Sex: All

Age: 18+

Code: NCT05296421

Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial